Article

Mark Zitter, MBA, Discusses Oncology Pathways

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.

Related Videos
Screenshot of an interview with Evangelia Vlachou, MD
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health
Screenshot of an interview with Barry Goy, MD
Gladys Antelo Allen
Dr Michael Bernstein
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
Debra Patt, MD, PhD, MBA, MPH
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Mikkael Sekeres, MD
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo